Irisin has shown potential in preventing Alzheimer’s disease (AD)-associated neuronal loss, cognitive decline, synaptic damage, neuroinflammation (e.g., by inhibiting microglia activation, IL-1β expression, and neutrophil infiltration), oxidative stress, and neuropathological changes (e.g., reducing Aβ deposits and NFTs). This evidence concerns the gene IL1B and early-onset autosomal dominant Alzheimer disease.